Biopharmaceutical companies have seen fewer layoffs in the first half of 2026 compared to the previous year. However, the total number of job cuts for the full year may still match 2025 levels. This outcome hinges on a significant increase in layoffs during the second half of the year. Mergers and acquisitions activity, which has risen substantially, could also contribute to future workforce reductions. The size of individual layoff rounds and the impact of M&A will be key factors in determining the year's final tally.
July 23, 2026
https://www.biospace.com/job-trends/biopharma-layoffs-must-double-in-h2-for-2026-to-match-2025-cuts